15793-94-9

Usage

Uses

Used in Pharmaceutical Industry:
1-(isoquinolin-1-yl)hydrazine is used as a building block for the synthesis of various bioactive molecules, contributing to the development of new pharmaceuticals with potential therapeutic applications.
Used in Dye and Pigment Production:
1-(isoquinolin-1-yl)hydrazine is utilized in the production of dyes and pigments, taking advantage of its chemical properties to create a range of colorants for different industries.
Organic Synthesis:
Due to its potential to undergo various chemical reactions, 1-(isoquinolin-1-yl)hydrazine serves as a versatile intermediate in organic synthesis, enabling the creation of a wide array of chemical compounds for diverse applications.

InChI:InChI=1/C9H9N3/c10-12-9-8-4-2-1-3-7(8)5-6-11-9/h1-6H,10H2,(H,11,12)

Upstream product

• 119-65-3 isoquinoline 
• 19493-44-8 1-chloroisoquinoline 
• 491-30-5 1-hydroxyisoquinoline 
• 302-01-2 hydrazine 
• 491-30-5 1-isoquinolone 

Downstream Products

• 103837-20-3 N-Isoquinolin-1-yl-N'-[1-phenyl-1-pyridin-2-yl-meth-(Z)-ylidene]-hydrazine 
• 440-54-0 s-Triazolo<3,4-a>isochinolin 
• 7639-56-7 3-Methyl-s-triazolo<3,4-a>isochinolin 
• 2746-49-8 benzaldehyde isoquinolin-1-ylhydrazone 
• 3223-55-0 3-phenyl-[1,2,4]triazolo[3,4-a]isoquinoline 
• 1448812-54-1 N-(3-chloro-5-(((4-cyano-1-(isoquinolin-1-yl)-3-methyl-1H-pyrazol-5-yl)amino)methyl)-2-hydroxyphenyl)propionamide 
• 877403-00-4 tert-butyl [(1R)-1-(2,5-difluorobenzyl)-3-(2-isoquinolin-1-ylhydrazino)-3-oxopropyl]carbamate 

Relevant academic research and scientific papers

Synthesis of Some Isoquinolyl-1-hydrazones and Spectrophotometric Characterization of Some of Their Transition-Metal Chelates

Synthesis of 1-hydrazinoisoquinoline and nine of its hydrazones is reported together with spectrophotometric data from the visible spectral region for their chelates with iron(II), cobalt(II), nickel(II), and copper(II).

Metal free [4+1] and [5+1] annulation reactions to prepare heterocycles using DMF and its derivatives as one-carbon source

1,2,4-Triazolo[3,4-a]pyridines and related heterocycles and substituted triazines were commonly discovered scaffolds in a variety of pharmaceutical and agrochemical agents. Herein, we report a highly efficient and practical method using DMF and its derivative for the [4+1] and [5+1] annulation reactions to prepare these heterocycles. This metal free reaction takes advantages of shelf stable DMF as solvent and carbon donor, imidazole chloride as a catalyst, the mild reaction condition tolerates a broad substrate range and substitutes. The prepared 3-unsubstituted 1,2,4-triazolo[3,4-a]pyridine and derivatives allow further introduction of a variety of functional group1 at 3-position.

CALPAIN MODULATORS AND THERAPEUTIC USES THEREOF

Disclosed herein are small molecule calpain modulator compositions, pharmaceutical compositions, the use and preparation thereof.

PYRAZOLE DERIVATIVES AS MALT1 INHIBITORS

Disclosed are compounds, compositions and methods for treating of diseases, syndromes, conditions, and disorders that are affected by the modulation of MALT1. Such compounds are represented by Formula (I) as follows: wherein R1, R2, R3, R4, R5, R6, R5, G1, and G2 are defined herein.

PYRAZOLE AND PYRROLE COMPOUNDS USEFUL IN TREATING IRON DISORDERS

This invention is directed to pyrazole and pyrrole compounds, for example, compounds of formula (I): wherein R1, R2, R3 and R4 are as defined herein, as stereoisomers, enantiomers, tautomers thereof or mixtures thereof; or pharmaceutically acceptable salts, solvates or prodrugs thereof, for the treatment of iron disorders. This invention is also directed to pharmaceutical compositions comprising the compounds and methods of using the compounds to treat iron disorders.

FUSED TRIAZOLE DERIVATIVES AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES

The present invention is directed to novel fused triazole derivatives which are inhibitors of the dipeptidyl peptidase-IV enzyme ("DPP-IV inhibitors") and which are useful in the treatment or prevention of diseases in which the dipeptidyl peptidase-IV enzyme is involved, such as diabetes and particularly type 2 diabetes. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which the dipeptidyl peptidase-IV enzyme is involved.

Molecular yardsticks. Rigid probes to define the spatial dimensions of the benzodiazepine receptor binding site

A series of rigid planar azadiindoles (8a, 8b, and 8d), benzannelated pyridodiindoles (11a, 11b, and 11d), and indolopyridoimidazoles (11c, 20, and 24) were synthesized from 4-oxo-1,2,3,4-tetrahydro-β-carboline 5 via the Fischer indole cyclization with the appropriate arylhydrazines. These analogues were employed as probes ('molecular yardsticks') to define the spatial dimensions of the lipophilic regions of the benzodiazepine receptor (BzR) binding cleft. Benzannelated indoles 11a-d and indolopyridoimidazoles 20 and 24 were important in establishing an area of negative interaction (S1, see Figure 6, part b) in the binding cleft common to the interactions of both inverse agonists and agonists. Data from this chemical and computer- assisted analysis of the pharmacophore (see Figure 6) indicates that inverse agonists and agonists bind to the same binding region, but the pharmacophoric descriptors required for the two activities are different, in keeping with previous studies with these planar ligands. However, the hydrogen bond donating site H1 and the lipophilic region L1 in the receptor binding site are common interactions experienced by both series of ligands. The low affinities of both indolo[3,2-c]carbazole (3a) and indolo[3,2-b]isoquinoline (3b) for the BzR are consonant with the requirements of a hydrogen bond acceptor interaction at donor site H1 and a hydrogen bond donor interaction at acceptor site A2 for potent inverse agonist activity in the β-carboline series. The hydrochloride salts of 1-aza- 8a (IC50 10.6 nM), 2-aza- 8b (IC50 51.5 nM), and 4-azadiindole 8d (IC50 11.2 nM) were found to be much more soluble in water than the corresponding salt of the parent diindole 2. Moreover, aza analogues 8a and 8b were shown to be partial inverse agonists with proconvulsant potencies comparable to that of the parent diindole 2.